AZD8931 (Sapitinib) is primarily investigated for its potential in cancer treatment, particularly in targeting specific types of tumors. It functions as an inhibitor of the epidermal growth factor receptor (EGFR) family, which includes HER1, HER2, and HER3 receptors. These receptors are often overexpressed in various cancers, leading to uncontrolled cell proliferation and survival. In clinical research, AZD8931 has been studied for its efficacy in treating breast cancer, especially in cases where HER2-positive tumors are resistant to other therapies. It is also explored in non-small cell lung cancer (NSCLC) and other solid tumors where EGFR signaling plays a critical role. By blocking these receptors, the compound aims to inhibit tumor growth and improve patient outcomes. Additionally, AZD8931 is being evaluated in combination with other chemotherapeutic agents to enhance its therapeutic effects and overcome resistance mechanisms. Its ability to target multiple receptors in the EGFR family makes it a promising candidate for personalized cancer therapy, particularly in patients with specific genetic mutations or receptor profiles. Ongoing studies continue to assess its safety, efficacy, and optimal dosing regimens in various cancer types.